Omeprazole
- Generic Name
- Omeprazole
- Brand Names
- Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 73590-58-6
- Unique Ingredient Identifier
- KG60484QX9
- Background
Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approva...
- Indication
Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:
• Treatment of active duodenal ulcer in adults
• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer
recurrence in adults
• Treatment of active benign gastric ulcer in adults
...
- Associated Conditions
- Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
- Associated Therapies
- -
Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates
- Conditions
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 14
- Registration Number
- NCT01911728
- Locations
- 🇿🇦
Parexel, George, South Africa
🇿🇦Parexel/Qdot Pharma, Port Elizabeth, South Africa
Ranitidin Versus Omeprazole in Patients Taking Clopidogrel
- Conditions
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 92
- Registration Number
- NCT01896557
Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 262
- Registration Number
- NCT01851863
- Locations
- 🇨🇳
Renji Hospital, Shanghai, China
CYP2C19 Genotype Predictor of Gastric Acid Suppression
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT01824199
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
The Impact of Proton Pump Inhibitors on the Fecal Microbiome
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 15
- Registration Number
- NCT01822977
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
The Therapeutic Role of Intravenous Albumin Administration for Peptic Ulcer Bleeding Patients With Hypoalbuminemia
- Conditions
- Interventions
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 91
- Registration Number
- NCT01822600
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)
- Conditions
- Interventions
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT01813552
Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- Soroka University Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT01795794
A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole
- Conditions
- Interventions
- First Posted Date
- 2013-02-08
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Presidio Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01786382
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
Laryngomalacia Study
- Locations
- 🇨🇦
BC Children's Hospital, Vancouver, British Columbia, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.